Skip to main content

Table 2 Long term regimen of Azithromycin and Tobramycin in stable phase of 37 children

From: Prognosis and treatment of 46 Chinese pediatric cystic fibrosis patients

Variables N = 37
Azithromycin -no/total no (%) 34/37 (91.89)
 Number of actual users 31/34 (91.18)
 Duration -month 25.69 ± 16.78 (0.5–62, median 23)
 Onset time -month 3.77 ± 2.92 (1–12, median 3.0)
 Side effect -no/total no (%) 3/34 (8.82)
Tobramycin -no/total no (%) 31/37 (83.78)
 Number of actual users -no/total no (%) 29/31 (93.55)
 Duration -month 24.60 ± 13.40 (0.5–48, median 24)
 Side effect -no/total no (%) 0/31 (0.00)